Familial vulnerability to an unusual cognitive adverse effect of topiramate: Discussion of mechanisms

Indian Journal of Psychiatry

Volumn 52, Issue 3, 2010, Pages 260-263

  Andrade, Chittaranjan ^c   Bhakta, Savita G ^a   Fernandes, Praveen P ^b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NONE

Author keywords

Cognitive impairment; genetic vulnerability; topiramate

Indexed keywords

AMFEBUTAMONE; ESCITALOPRAM; LAMOTRIGINE; TOPIRAMATE;

ADULT; ARTICLE; BIPOLAR II DISORDER; CASE REPORT; COGNITION; COGNITIVE DEFECT; DRUG MECHANISM; DRUG WITHDRAWAL; ECHOLALIA; FEMALE; GENETIC VARIABILITY; HUMAN; PARANOID PERSONALITY DISORDER; SEDATION; SIDE EFFECT;

EID: 77958040992     PISSN: 00195545     EISSN: 19983794     Source Type: Journal    
DOI: 10.4103/0019-5545.70986     Document Type: Article

References (46)

1. Raskin P, Donofrio PD, Rosenthal NR, Hewitt DJ, Jordan DM, Xiang J, et al. Topiramate vs placebo in painful diabetic neuropathy: Analgesic and metabolic effects. Neurology 2004;63:865-73
2. Johnson BA, Ait-Daoud N, Bowden CL, DiClemente CC, Roache JD, Lawson K, et al. Oral topiramate for treatment of alcohol dependence: A randomised controlled trial. Lancet 2003;361:1677-85
3. Johnson BA, Ait-Daoud N, Akhtar FZ, Ma JZ. Oral topiramate reduces the consequences of drinking and improves the quality of life of alcohol-dependent individuals: A randomized controlled trial. Arch Gen Psychiatry 2004;61:905-12
4. Johnson BA, Ait-Daoud N, Akhtar FZ, Javors MA. Use of oral topiramate to promote smoking abstinence among alcohol-dependent smokers: A randomized controlled trial. Arch Intern Med 2005;165:1600-5
5. Johnson BA, Rosenthal N, Capece JA, Wiegand F, Mao L, Beyers K, et al. For the Topiramate for Alcoholism Advisory Board and the Topiramate for Alcoholism Study Group. Topiramate for treating alcohol dependence: A randomized controlled trial. JAMA 2007;298:1641-51
6. Johnson BA, Rosenthal N, Capece JA, Wiegand F, Mao L, Beyers K, et al. for the Topiramate for Alcoholism Advisory Board and the Topiramate for Alcoholism Study Group. Improvement of physical health and quality of life of alcohol-dependent individuals with topiramate treatment: US multisite randomized controlled trial. Arch Intern Med 2008;168:1188-99
7. Reid MS, Palamar J, Raghavan S, Flammino F. Effects of topiramate on cue-induced cigarette craving and the response to a smoked cigarette in briefy abstinent smokers. Psychopharmacology (Berl) 2007;192:147-58
8. Toplak H, Hamann A, Moore R, Masson E, Gorska M, Vercruysse F, et al. Effcacy and safety of topiramate in combination with metformin in the treatment of obese subjects with type 2 diabetes: A randomized, double-blind, placebo-controlled study. Int J Obes (Lond) 2007;31:138-46
9. Nickel C, Tritt K, Muehlbacher M, Pedrosa Gil F, Mitterlehner FO, Kaplan P, et al. Topiramate treatment in bulimia nervosa patients: A randomized, double-blind, placebo-controlled trial. Int J Eat Disord 2005;38:295-300
10. Nickel MK, Nickel C, Muehlbacher M, Leiberich PK, Kaplan P, Lahmann C, et al. Infuence of topiramate on olanzapine-related adiposity in women: A random, double-blind, placebo-controlled study. J Clin Psychopharmacol 2005;25:211-7
11. Kim JH, Yim SJ, Nam JH. A 12-week, randomized, open-label, parallel-group trial of topiramate in limiting weight gain during olanzapine treatment in patients with schizophrenia. Schizophr Res 2006;82:115-7
12. Tucker P, Trautman RP, Wyatt DB, Thompson J, Wu SC, Capece JA, et al. Effcacy and safety of topiramate monotherapy in civilian posttraumatic stress disorder: A randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2007;68:201-6
13. Chengappa KN, Schwarzman LK, Hulihan JF, Xiang J, Rosenthal NR for the Clinical Affairs Product Support Study-168 Investigators. Adjunctive topiramate therapy in patients receiving a mood stabilizer for bipolar I disorder: A randomized, placebo-controlled trial. J Clin Psychiatry 2006;67:1698-706
14. Kushner SF, Khan A, Lane R, Olson WH. Topiramate monotherapy in the management of acute mania: Results of four double-blind placebo-controlled trials. Bipolar Disord 2006;8:15-27
15. Aldenkamp AP, De Krom M, Reijs R. Newer antiepileptic drugs and cognitive issues. Epilepsia 2003;44:21-9
16. Lee S, Sziklas V, Andermann F, Farnham S, Risse G, Gustafson M, et al. The effects of adjunctive topiramate on cognitive function in patients with epilepsy. Epilepsia 2003;44:339-47
17. Gomer B, Wagner K, Frings L, Saar J, Carius A, Harle M, et al. The infuence of antiepileptic drugs on cognition: A comparison of levetiracetam with topiramate. Epilepsy Behav 2007;10:486-94
18. Lee HW, Jung DK, Suh CK, Kwon SH, Park SP. Cognitive effects of low-dose topiramate monotherapy in epilepsy patients: A 1-year follow-up. Epilepsy Behav 2006;8:736-41
19. Thompson PJ, Baxendale SA, Duncan JS, Sander JWAS. Effects of topiramate on cognitive function. J Neurol Neurosurg Psychiatry 2000;69:636-41
20. Aarsen FK, van den Akker EL, Drop SL, Catsman-Berrevoets CE. Effect of topiramate on cognition in obese children. Neurology 2006;67:1307-8
21. Gross-Tsur V, Shalev RS. Reversible language regression as an adverse effect of topiramate treatment in children. Neurology 2004;62:299-300
22. Aldenkamp AP, Baker G, Mulder OG, Chadwick D, Cooper P, Doelman J, et al. A multicenter, randomized clinical study to evaluate the effect on cognitive function of topiramate compared with valproate as add-on therapy to carbamazepine in patients with partial-onset seizures. Epilepsia 2000;41:1167-78
23. Mula M, Trimble MR, Thompson P, Sander JW. Topiramate and word-fnding diffculties in patients with epilepsy. Neurology 2003;60:1104-7
24. th ed. Washington, DC: American Psychiatric Association, 1994.
25. Blum D, Meador K, Biton V, Fakhoury T, Shneker B, Chung S, et al. Cognitive effects of lamotrigine compared with topiramate in patients with epilepsy. Neurology 2006;67:400-6
26. Gualtieri CT, Johnson LG. Comparative neurocognitive effects of 5 psychotropic anticonvulsants and lithium. MedGenMed 2006;8:46
27. Meador KJ. Cognitive effects of levetiracetam versus topiramate. Epilepsy Curr 2008;8:64-5
28. Shank RP, Gardocki JF, Streeter AJ, Maryanoff BE. An overview of the preclinical aspects of topiramate: Pharmacology, pharmacokinetics, and mechanism of action. Epilepsia 2000;41:S3-9
29. White HS. Molecular pharmacology of topiramate: Managing seizures and preventing migraine. Headache 2005;45:S48-56
30. Guerrini R, Parmeggiani L. Topiramate and its clinical applications in epilepsy. Expert Opin Pharmacother 2006;7:811-23
31. Izquierdo I, Bevilaqua LR, Rossato JI, Bonini JS, Medina JH, Cammarota M. Different molecular cascades in different sites of the brain control memory consolidation. Trends Neurosci 2006;29:496-505
32. Ojemann LM, Ojemann GA, Dodrill CB, Crawford CA, Holmes MD, Dudley DL. Language disturbances as side effects of topiramate and zonisamide therapy. Epilepsy Behav 2001;2:579-84
33. Shank RP, Smith-Swintosky VL, Maryanoff BE. Carbonic anhydrase inhibition. Insight into the characteristics of zonisamide, topiramate, and the sulfamide cognate of topiramate. J Enzyme Inhib Med Chem 2008;23:271-6
34. Berent S, Sackellares JC, Giordani B, Wagner JG, Donofrio PD, Abou-Khalil B. Zonisamide (CI-912) and cognition: Results from preliminary study. Epilepsia 1987;28:61-7
35. Park SP, Hwang YH, Lee HW, Suh CK, Kwon SH, Lee BI. Long-term cognitive and mood effects of zonisamide monotherapy in epilepsy patients. Epilepsy Behav 2008;12:102-8
36. Glauser TA. Topiramate. Epilepsia 1999;40:S71-80
37. Andrade C. Confusion and dysphoria with low-dose topiramate in a patient with bipolar disorder. Bipolar Disord 2001;3:211-12
38. Fisher SE, Francks C. Genes, cognition and dyslexia: Learning to read the genome. Trends Cogn Sci 2006;10:250-7
39. Smith SD. Genes, language development, and language disorders. Ment Retard Dev Disabil Res Rev 2007;13:96-105
40. Zaccara G, Gangemi PF, Cincotta M. Central nervous system adverse effects of new antiepileptic drugs. A meta-analysis of placebo-controlled studies. Seizure 2008;17:405-21
41. Jansen JF, Aldenkamp AP, Marian Majoie HJ, Reijs RP, de Krom MC, Hofman PA, et al. Functional MRI reveals declined prefrontal cortex activation in patients with epilepsy on topiramate therapy. Epilepsy Behav 2006;9:181-5
42. Cappa SF, Ortelli P, Garibotto V, Zamboni M. Reversible nonfuent aphasia and left frontal hypoperfusion during topiramate treatment. Epilepsy Behav 2007;10:192-4
43. Chengappa KN, Gershon S, Levine J. The evolving role of topiramate among other mood stabilizers in the management of bipolar disorder. Bipolar Disord 2001;3:215-32
44. Tranel D. Neurology of language. Curr Opin Neurol Neurosurg 1992;5:77-82
45. Saur D, Kreher BW, Schnell S, K|mmerer D, Kellmeyer P, Vry MS, et al. Ventral and dorsal pathways for language. Proc Natl Acad Sci \USA 2008;105:18035-40
46. Wheeler SD. Donepezil treatment of topiramate-related cognitive dysfunction. Headache 2006;46:332-5